Neratinib: Inching Up on the Cure Rate of HER2 + Breast Cancer?

Neratinib was recently approved by the FDA for extended adjuvant treatment of HER2 breast cancer. The ExteNET trial showed improvement in invasive disease-free survival (iDFS) in the neratinib arm compared with placebo. The benefit was more pronounced in patients with estrogen receptor-positive (ER...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical cancer research 2018-08, Vol.24 (15), p.3483-3485
Hauptverfasser:	Unni, Nisha, Sudhan, Dhivya R, Arteaga, Carlos L
Format:	Artikel
Sprache:	eng
Schlagworte:	Breast cancer Cancer Crosstalk ErbB-2 protein Estrogen receptors Estrogens Invasiveness Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!